On December 13, CSPC PHARMA (01093.HK) spent 29.84 million Hong Kong dollars to repurchase 6.2 million shares.

On December 13th, Gelonghui reported that CSPC PHARMA (01093.HK) announced it would spend HKD 29.84 million to repurchase 6.2 million shares on December 13, 2024, with a repurchase price of HKD 4.79-4.85 per share.

Gelonghui FinanceDec 13 05:24 ET

CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland

MT NewswiresDec 13 04:48 ET

CSPC PHARMA (01093.HK) has entered into an exclusive licensing agreement with BEIGENE for SYH2039.

On December 13, Glori has announced that CSPC PHARMA (01093.HK) has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH ("BEIGENE") regarding the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as any Pharmaceutical that consists of or contains this compound for Global development, manufacturing, and commercialization. Under the terms and conditions of this agreement, the group agrees to grant BEIGENE exclusive rights to develop, manufacture, and commercialize this compound and this product globally.

Gelonghui FinanceDec 12 19:14 ET

Express News | CSPC Pharmaceutical - Exclusive License Agreement for Syh2039 With Beigene

ReutersDec 12 19:12 ET

CSPC PHARMA (01093.HK) canceled 57.58 million repurchased shares on December 10.

On December 10, Gelonghui reported that cspc pharma (01093.HK) announced the cancellation of a total of 57.58 million repurchased shares on December 10, 2024.

Gelonghui FinanceDec 10 03:45 ET

Announcement highlights | Longfor Group's sales exceeded 90 billion yuan this year; Mao Geping announced the lottery results, listed this morning.

In the first 11 months, longfor group achieved a total contract sales amount of 93 billion yuan, with contract sales of 8.5 billion yuan in November; cspc pharma's application for marketing approval for SYHX2011 to treat advanced breast cancer was accepted.

cls.cnDec 9 18:57 ET